News

JCRI composes part of USPI’s new 45,000 square-foot Canady Innovation Center (CIC), which houses a cross-functional team of global scientists, physicians, clinicians, healthcare professionals and engineers who collaborate

The collaboration, which will leverage the strengths of both organizations, is aimed at accelerating the development of transformational new therapies for these underserved patients. The biobank at CHOP’s

ONL101 is a first-in-class small molecule peptide currently under development to protect photoreceptors in retinal detachment, a condition for which the product has been granted orphan disease designation.

Vasostrict is the first and only vasopressin injection, USP, product with an NDA approved by the US FDA and it is indicated to increase blood pressure in adults

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. This is the company’s second approval to start a Phase

The open-label trial (Study 204) is designed to evaluate the safety of eteplirsen over 96 weeks of dosing, and will be conducted in DMD patients who are non-ambulant

Neuren intends to submit applications to the US Food and Drug Administration (FDA) for both Orphan Drug and Breakthrough Therapy designation. Neuren expects to meet with the FDA

Capstone has been created through the integration of H.I.G. portfolio companies Integrity Nutraceuticals in Spring Hill, TN and Cornerstone Research & Development in Ogden, UT. Capstone will compete

Rociletinib is the Company’s novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in